Näytä suppeat kuvailutiedot

dc.contributor.authorSievänen, Tero
dc.contributor.authorKorhonen, Tia‐Marje
dc.contributor.authorJokela, Tiina
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorLahtinen, Laura
dc.contributor.authorKuopio, Teijo
dc.contributor.authorLepistö, Anna
dc.contributor.authorSillanpää, Elina
dc.contributor.authorMecklin, Jukka‐Pekka
dc.contributor.authorSeppälä, Toni T.
dc.contributor.authorLaakkonen, Eija K.
dc.date.accessioned2022-11-08T11:29:40Z
dc.date.available2022-11-08T11:29:40Z
dc.date.issued2023
dc.identifier.citationSievänen, T., Korhonen, T., Jokela, T., Ahtiainen, M., Lahtinen, L., Kuopio, T., Lepistö, A., Sillanpää, E., Mecklin, J., Seppälä, T. T., & Laakkonen, E. K. (2023). Systemic circulating microRNA landscape in Lynch syndrome. <i>International Journal of Cancer</i>, <i>152</i>(5), 932-944. <a href="https://doi.org/10.1002/ijc.34338" target="_blank">https://doi.org/10.1002/ijc.34338</a>
dc.identifier.otherCONVID_159362492
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/83820
dc.description.abstractCirculating microRNAs (c-miRs) are small non-coding RNA molecules that migrate throughout the body and regulate gene expression. Global c-miR expression patterns (c-miRnomes) change with sporadic carcinogenesis and have predictive potential in early detection of cancers. However, there are no studies that have assessed whether c-miRnomes display similar potential in carriers of inherited pathogenic mismatch-repair gene variants (path_MMR), known as Lynch syndrome (LS), who are predisposed to highly increased cancer risk. Using high-throughput sequencing and bioinformatic approaches, we conducted an exploratory analysis to characterize systemic c-miRnomes of path_MMR carriers, sporadic rectal cancer patients and non-LS controls. We showed for the first time that cancer-free path_MMR carriers have a systemic c-miRnome of 40 differentially expressed c-miRs that can distinguish them from non-LS controls. The systemic c-miRnome of cancer-free path_MMR carriers also resembles the systemic c-miRnomes of cancer patients with or without path_MMR. Our pathway analysis linked the found differentially expressed c-miRs to carcinogenesis. A total of 508 putative target genes were identified for 32 out of 40 differentially expressed c-miRs, and 238 of them were enriched in cancer-related pathways. The most enriched c-miR-target genes include well-known oncogenes and tumor suppressor genes such as BCL2, AKT3, PIK3CA, KRAS, NRAS, CDKN1A and PIK3R1. Taken together, our findings suggest that LS and sporadic carcinogenesis share common biological pathways and alterations in these pathways can produce a c-miR signature which can track potential oncogenic stress in cancer-free path_MMR carriers. Therefore, c-miRs hold potential in monitoring the LS risk stratification patterns during clinical surveillance or cancer management.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesInternational Journal of Cancer
dc.rightsCC BY 4.0
dc.subject.otherhereditary cancer
dc.subject.othernext generation sequencing
dc.titleSystemic circulating microRNA landscape in Lynch syndrome
dc.typeresearch article
dc.identifier.urnURN:NBN:fi:jyu-202211085121
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineGerontologia ja kansanterveysfi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.contributor.oppiaineGerontology and Public Healthen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange932-944
dc.relation.issn0020-7136
dc.relation.numberinseries5
dc.relation.volume152
dc.type.versionpublishedVersion
dc.rights.copyright© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
dc.rights.accesslevelopenAccessfi
dc.type.publicationarticle
dc.relation.grantnumber
dc.relation.grantnumber341750
dc.relation.grantnumber101026706
dc.relation.grantnumber101026706
dc.relation.projectidinfo:eu-repo/grantAgreement/EC/H2020/101026706/EU//cmiRCan
dc.subject.ysosuolistosyövät
dc.subject.ysoperinnölliset taudit
dc.subject.ysosyöpätaudit
dc.subject.ysobioinformatiikka
dc.subject.ysoLynchin oireyhtymä
dc.subject.ysosekvensointi
dc.subject.ysomikro-RNA
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p25845
jyx.subject.urihttp://www.yso.fi/onto/yso/p19997
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p15748
jyx.subject.urihttp://www.yso.fi/onto/yso/p23697
jyx.subject.urihttp://www.yso.fi/onto/yso/p25917
jyx.subject.urihttp://www.yso.fi/onto/yso/p27218
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1002/ijc.34338
dc.relation.funderPäivikki ja Sakari Sohlberg Foundationen
dc.relation.funderResearch Council of Finlanden
dc.relation.funderEuropean Commissionen
dc.relation.funderPäivikki ja Sakari Sohlbergin Säätiöfi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderEuroopan komissiofi
jyx.fundingprogramFoundationen
jyx.fundingprogramAcademy Research Fellow, AoFen
jyx.fundingprogramMSCA Individual Fellowship (IF)en
jyx.fundingprogramSäätiöfi
jyx.fundingprogramAkatemiatutkija, SAfi
jyx.fundingprogramMSCA Individual Fellowship (IF)fi
jyx.fundinginformationE.K. Laakkonen was supported by the Päivikki and Sakari Sohlberg Foundation. E. Sillanpää was supported by the Academy of Finland research fellowship (grant number: 341750). T.T. Seppälä was supported by Finnish Medical Foundation, Emil Aaltonen Foundation, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Foundation, Relander Foundation, Academy of Finland (grant number: 338657), HUS State Research Funds (TYH2021123 and TYH2022323) and iCAN Digital Precision Medicine Flagship. J-P. Mecklin was supported by Jane and Aatos Erkko Foundation, Finnish Cancer Foundation and KYS State Research Funds. Funding programs: MSCA Individual Fellowship (IF), Additional information about funding: This work was supported by T.J.-the EU Marie Skłodowska-Curie Actions [Grant agreement ID: 101026706)
datacite.isSupplementedBy.doi10.17011/jyx/dataset/93204
datacite.isSupplementedByLaakkonen, Eija; Seppälä, Toni; Mecklin, Jukka-Pekka. (2024). <i>Lynch Syndrome, lifestyle habits and biomarkers</i>. University of Jyväskylä. <a href="https://doi.org/10.17011/jyx/dataset/93204" target="_blank">https://doi.org/10.17011/jyx/dataset/93204</a>. <a href="http://urn.fi/URN:NBN:fi:jyu-202402011711">https://urn.fi/URN:NBN:fi:jyu-202402011711</a>
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0